Relay Therapeutics, Inc.

Historical 13F Holders

Symbol
RLAY
CUSIP
75943R102
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 75943R102 since 12/18/2024, newest first.

Filer % of Class Filed
Commodore Capital LP 13G/A Amendment 3
5.5% 8/14/2026
Event 6/30/2026
Perceptive Advisors LLC 13G/A Amendment 1
6.4% 8/10/2026
Event 6/30/2026
FMR LLC 13G/A Amendment 1
10.0% 8/7/2026
Event 7/31/2026
FMR LLC 13G
9.4% 8/6/2026
Event 6/30/2026
Point72 Asset Management, L.P. 13G/A Amendment 2
0% 5/15/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 5 0% 3/27/2026
Event 3/13/2026
Perceptive Advisors LLC 13G
5.3% 3/19/2026
Event 3/12/2026
Casdin Capital, LLC 13G/A Amendment 2
7.5% 2/17/2026
Event 12/31/2025
Casdin Capital, LLC 13G/A Amendment 2
7.5% 2/17/2026
Event 12/31/2025
Commodore Capital LP 13G/A Amendment 2
9.9% 11/14/2025
Event 9/30/2025
Commodore Capital LP 13G/A Amendment 1
7.8% 8/14/2025
Event 6/30/2025
Point72 Asset Management, L.P. 13G/A Amendment 1
7.8% 8/14/2025
Event 6/30/2025
Vanguard Group Inc 13G/A Amendment 4 5.5% 7/29/2025
Event 6/30/2025
Commodore Capital LP 13G
5.8% 5/15/2025
Event 5/8/2025
Vanguard Group Inc 13G/A Amendment 3 7.1% 4/30/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 4 6.1% 4/17/2025
Event 3/31/2025
Point72 Asset Management, L.P. 13G
5.7% 3/20/2025
Event 3/14/2025
BlackRock, Inc. 13G/A Amendment 3 8.8% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 6 822 k $14.8 M
2026 Q2 271 250 M $4.75 B
2026 Q1 253 185 M $1.84 B
2025 Q4 234 174 M $1.47 B
2025 Q3 207 167 M $870 M
2025 Q2 212 171 M $593 M
2025 Q1 215 167 M $439 M
2024 Q4 206 164 M $676 M
2024 Q3 205 169 M $1.20 B
2024 Q2 187 133 M $869 M
2024 Q1 197 138 M $1.15 B
2023 Q4 184 135 M $1.49 B
2023 Q3 178 130 M $1.10 B
2023 Q2 170 130 M $1.64 B
2023 Q1 168 131 M $2.16 B
2022 Q4 174 134 M $2.01 B
2022 Q3 170 124 M $2.76 B
2022 Q2 152 121 M $2.02 B
2022 Q1 148 113 M $3.39 B
2021 Q4 138 113 M $3.47 B
2021 Q3 146 91.8 M $2.89 B
2021 Q2 127 91.2 M $3.34 B
2021 Q1 139 87.6 M $3.03 B
2020 Q4 117 87.7 M $3.65 B
2020 Q3 96 90.3 M $3.64 B